Givlaari

Search documents
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Overview: A Deep Dive into Financials and Developments
Financial Modeling Prep· 2025-10-04 02:00
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is making significant strides in RNA interference (RNAi) therapeutics, focusing on rare diseases and cardiovascular conditions.The company's revenue boost is attributed to its diversified drug portfolio, including Amvuttra, which has seen approval in the U.S. and EU.Despite challenges such as a negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18, Alnylam shows strong financial performance with a current ratio of 2.80.Alnylam P ...
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Benzinga· 2025-08-01 18:28
Core Viewpoint - Alnylam Pharmaceuticals reported strong second-quarter earnings and raised its 2025 sales guidance, indicating positive momentum in its product launches and overall financial performance [1][3]. Financial Performance - The company reported adjusted earnings of 32 cents for Q2 2025, a decrease from 56 cents year-over-year, but significantly better than analysts' expectations of a loss of 79 cents [1]. - Quarterly sales reached $773.69 million, reflecting a 17% year-over-year increase and surpassing the consensus estimate of $638.55 million [1]. Product Revenue - Global net product revenues for Amvuttra and Onpattro were $492 million and $53 million, respectively, while Givlaari and Oxlumo generated $81 million and $47 million in revenue for the same quarter [2]. - The launch of Amvuttra for ATTR-CM has been particularly successful, with approximately 1,400 patients treated by June 30, 2025, contributing to an estimated $150 million increase in revenue [4]. Guidance and Analyst Outlook - Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion, exceeding the consensus of $2.89 billion [3]. - Analysts from Chardan Research and William Blair expressed positive outlooks, with Chardan highlighting the strong start of Amvuttra's launch [3][6]. Analyst Ratings and Price Forecasts - Various analysts have upgraded their price forecasts for Alnylam, with Chardan raising its target from $325 to $400, and UBS increasing its forecast from $403 to $550 [5][8]. - Morgan Stanley maintained an Equal-Weight rating while increasing its price forecast from $312 to $405, and Piper Sandler raised its target from $304 to $449 [7].
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
ZACKS· 2025-08-01 16:51
Core Insights - Alnylam Pharmaceuticals reported second-quarter 2025 earnings of $0.32 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.03, primarily due to increased revenues from its lead drug, Amvuttra [1][11] - Total revenues for the quarter reached $773.7 million, exceeding the Zacks Consensus Estimate of $673 million, and reflecting a 17% year-over-year increase [2] - The company's net product revenues were $672.2 million, a 64% increase year-over-year, driven by strong demand for Amvuttra, Givlaari, and Oxlumo [3] Revenue Breakdown - Alnylam's net product revenues from Amvuttra amounted to $492 million, representing a 114% increase year-over-year, aided by expanded label use and patient switches from Onpattro [8][11] - Givlaari generated sales of $80.8 million, a 30% year-over-year increase, while Oxlumo recorded revenues of $46.9 million, up 15% year-over-year [9] - Net revenues from collaborators were $61.5 million, down 73% from the previous year, primarily due to a significant milestone payment received in the prior quarter [4] Financial Guidance - Alnylam raised its 2025 product revenue guidance to a range of $2.65 billion to $2.8 billion, up from the previous range of $2.05 billion to $2.25 billion [11][16] - The guidance for net revenues from collaborations and royalties remains unchanged at $650 million to $750 million [16] Research and Development - Adjusted R&D expenses increased by 11% year-over-year to $274.1 million, reflecting costs associated with new studies in partnership with Roche [13] - Adjusted SG&A expenses rose by 26% year-over-year to $261.2 million, driven by higher employee compensation and marketing investments related to Amvuttra [14] Cash Position - As of June 30, 2025, Alnylam's cash, cash equivalents, and marketable securities totaled $2.86 billion, an increase from $2.63 billion as of March 31, 2025, primarily due to net cash inflows from operating activities [15]
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-07-31 15:31
Core Insights - Alnylam Pharmaceuticals reported a revenue of $773.69 million for the quarter ended June 2025, reflecting a year-over-year increase of 17.3% and a surprise of +14.96% over the Zacks Consensus Estimate of $673 million [1] - The company's EPS was $0.32, down from $0.56 in the same quarter last year, with an EPS surprise of +1166.67% compared to the consensus estimate of -$0.03 [1] Revenue Breakdown - Product revenues were $672.21 million, exceeding the average estimate of $540.14 million by analysts, representing a year-over-year increase of +63.9% [4] - Royalty revenue reached $39.98 million, surpassing the average estimate of $32.74 million, with a year-over-year change of +78.5% [4] - Net Product Revenue from Oxlumo was $46.87 million, slightly above the estimated $46.64 million, marking a +15.4% change year over year [4] - Net Product Revenue from Givlaari was $80.85 million, exceeding the average estimate of $72.59 million, reflecting a +30.1% year-over-year increase [4] - Net Product Revenue from Amvuttra was $491.95 million, significantly higher than the estimated $365.41 million, showing a +113.8% change compared to the previous year [4] - Net Product Revenue from Onpattro was $52.24 million, below the average estimate of $45.89 million, indicating a -32.4% year-over-year decline [4] Research Collaborator Revenues - Net revenues from research collaborators totaled $61.5 million, falling short of the average estimate of $90.07 million, representing a -73% change year over year [4] - Other net revenues from research collaborators were $10.69 million, exceeding the estimated $3 million, with a remarkable +872.4% change compared to the previous year [4] - Net revenues from Regeneron Pharmaceuticals were $32.54 million, significantly lower than the estimated $17.5 million, reflecting an -84.3% change year over year [4] - Net revenues from Roche were $18.27 million, surpassing the average estimate of $12 million, with a +10.7% year-over-year change [4] Stock Performance - Alnylam's shares returned +3% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
ZACKS· 2025-06-10 14:11
Core Insights - Alnylam Pharmaceuticals has received European Commission approval for the label expansion of its RNAi therapeutic Amvuttra to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy [1][9] - Year-to-date, Alnylam's stock has increased by 29.1%, significantly outperforming the industry, which has seen a decline of 0.9% [2] Approval Details - The European Commission's approval was based on positive results from the late-stage HELIOS-B study, where Amvuttra met all 10 pre-specified primary and secondary endpoints [3][9] - The HELIOS-B trial demonstrated statistically significant reductions in all-cause mortality and recurrent cardiovascular events, along with major improvements in functional capacity, health status, and heart failure symptoms [4][9] Competitive Advantage - Amvuttra is administered quarterly via subcutaneous injection, providing an advantage over existing therapies that require daily oral dosing [5] - The drug's novel RNAi mechanism allows for rapid knockdown of transthyretin (TTR), addressing the disease at its source [6] Market Impact - The approval in the EU follows similar approvals in the United States and Brazil, expanding Amvuttra's global footprint [6] - Alnylam reported better-than-expected first-quarter 2025 results, with revenue growth driven by increasing Amvuttra sales due to heightened patient demand [10][11]